Annual Drug Patent Expirations for STENDRA
Stendra is a drug marketed by Metuchen Pharms and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for STENDRA.
This drug has fifty-three patent family members in twenty-six countries.
The generic ingredient in STENDRA is avanafil. Two suppliers are listed for this compound. Additional details are available on the avanafil profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com